| VKA users n = 319 | DOAC users n = 229 | P-value | ||
---|---|---|---|---|---|
Sex, (%) | 0.7 | ||||
 Male | 46 | 48 |  | ||
 Female | 54 | 52 |  | ||
Mean age (SD) | 78,2 | (5,2) | 77,5 | (4,9) | 0.2 |
VKA users (%) | |||||
 Acenocoumarol | 53 |  |  | ||
 Phenprocoumon | 47 |  |  | ||
DOAC users (%) | |||||
 Dabigatran |  | 33 |  | ||
 Rivaroxaban |  | 31 |  | ||
 Apixaban |  | 28 |  | ||
 Edoxaban |  | 8 |  | ||
TAI users (%) | 1 | 1 | 0.7 | ||
Administrating tranexamic acid (%) | 30 | 39 | 0.02 | ||
Comorbidities (%) | |||||
 Coronary heart disease | 19 | 23 | 0.3 | ||
 CVA/TIA | 20 | 19 | 0.7 | ||
 Decompensatio cordis | 20 | 14 | 0.1 | ||
 Diabetes mellitus | 3 | 6 | 0.7 | ||
 Valvular heart disease | 23 | 10 |  < 0.001 | ||
 Hypertension | 67 | 63 | 0.4 | ||
 Peripheral arterial disease | 4 | 8 | 0.1 | ||
 Heart rhythm disorder | 84 | 91 | 0.02 | ||
 Thrombosis | 17 | 12 | 0.1 | ||
 Clotting disorder | 1 | 0 | 0.1 | ||
Renal impairment (%) | 13 | 9 | 0.2 | ||
 eGFR 30—50 | 11 | 8 |  | ||
 eGFR < 30 | 2 | 1 |  | ||
Surgical bleeding risk (%) | Â | Â | 0.3 | ||
 Low | 0 | 0 |  | ||
 Intermediate | 17 | 14 |  | ||
 High | 83 | 86 |  | ||
ASA score (%) | Â | Â | 0.3 | ||
 II | 50 | 50 |  | ||
 III | 48 | 49 |  | ||
 IV | 2 | 1 |  | ||
Tourniquet use (%) | 22 | 26 | 0.3 | ||
Bellovac drain (%) | 15 | 13 | 0.4 |